

ABSOLUTE CONFIGURATIONS OF ENANTIOMERIC K-REGION *CIS*-5,6-DIHYDRODIOLS OF  
12-METHYLBENZ[*A*]ANTHRACENE AND 7-BROMO-12-METHYLBENZ[*A*]ANTHRACENE

Shen K. Yang<sup>\*a</sup>, Mohammad Mushtaq<sup>a</sup>, Henri B. Weems<sup>a</sup>, and Peter P. Fu<sup>b</sup>

<sup>a</sup>Department of Pharmacology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799 U.S.A. and

<sup>b</sup>National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079 U.S.A.

**ABSTRACT:** The absolute configurations of enantiomeric 7-bromo-12-methylbenz[*a*]anthracene *cis*-5,6-dihydrodiols (**3**) were determined by exciton chirality circular dichroism method. The absolute configurations of enantiomeric 12-methylbenz[*a*]anthracene *cis*-5,6-dihydrodiols (**1**) were determined by debromination of enantiomeric **3** of known absolute stereochemistry.

The hydroxyl groups of K-region *trans*-dihydrodiols of polycyclic aromatic hydrocarbons (PAHs) can assume either a quasidiequatorial or a quasidaxial conformation.<sup>1</sup> The absolute configurations of enantiomeric *trans*-dihydrodiols of either conformation can be determined by the exciton chirality circular dichroism (CD) method.<sup>2,3</sup> In the absence of steric and/or electronic constraints, each of the two hydroxyl groups of *cis*-dihydrodiols of PAHs (e.g., 12-methylbenz[*a*]anthracene (12-methyl-BA) *cis*-5,6-dihydrodiol, **1**) adopts either a quasidaxial or a quasiequatorial conformation. Because of this dual conformational possibility, the absolute configuration of enantiomeric *cis*-dihydrodiols such as **1** cannot be determined by the exciton chirality CD method (see below).

When an alkyl or a halo substituent is present at a *peri* position (e.g., the 7-substituent in 7,12-dimethyl-BA, **2** and in 7-bromo-12-methyl-BA, **3**), the hydroxyl group *peri* to the substituent is forced to adopt a quasidaxial conformation due to either steric hindrance (e.g., **2**)<sup>3</sup> or electronic repulsion (e.g., **3**)<sup>4-6</sup> imposed by the *peri* substituent. The hydroxyl group distant to the *peri* substituent adopts a quasiequatorial conformation. The absolute configuration of enantiomeric *cis*-dihydrodiols that have a locked conformation (such as **2**)<sup>7</sup> can thus be determined by the exciton chirality CD method.<sup>2,8</sup>

Recently chiral columns (see Table 1 for definition of the columns used in this study) have been employed to resolve enantiomers of a large number of mono-ols and diols of PAHs.<sup>8-12</sup> Enantiomers of 1, 2, and 3 can be resolved by at least three of the four chiral columns tested (Table 1). The establishment of absolute configuration-elution order relationship of the CSP-HPLC resolved enantiomers will greatly enhance our understanding of the chiral recognition mechanisms responsible for enantiomeric separations.

The CD spectrum of the enantiomeric 1 more strongly retained by (*S*)-DNBL-I (Table 1) is shown in Fig. 1A. This enantiomer was converted to a *bis-p-N,N*-dimethylaminobenzoate by reac-

Table 1. CSP-HPLC Resolution of K-region *cis*-Dihydrodiol Enantiomers of 12-Methyl-BA, 7-Bromo-12-methyl-BA, and 7,12-Dimethyl-BA.<sup>a</sup>

Dihydrodiol	CSP <sup>b</sup>	R <sub>t</sub> <sup>c</sup>	RV <sup>d</sup>
12-methyl-BA	( <i>R</i> )-DNBPG-I	23.5 (5 <i>R</i> ,6 <i>S</i> )	1.6
<i>cis</i> -5,6-dihydrodiol ( <u>1</u> ) <sup>e</sup>	( <i>R</i> )-DNBPG-C	15.6 (5 <i>R</i> ,6 <i>S</i> )	1.2
(5e,6a & 5a,6e) <sup>f</sup>	( <i>S</i> )-DNBL-I	20.4 (5 <i>S</i> ,6 <i>R</i> )	3.3
	( <i>S</i> )-DNBL-C	12.5 (5 <i>S</i> ,6 <i>R</i> )	2.2
7,12-dimethyl-BA <sup>g</sup>	( <i>R</i> )-DNBPG-I	16.0 (5 <i>S</i> ,6 <i>R</i> )	1.0
<i>cis</i> -5,6-dihydrodiol ( <u>2</u> )	( <i>R</i> )-DNBPG-C	11.6 (5 <i>S</i> ,6 <i>R</i> )	1.3
(5e,6a)	( <i>S</i> )-DNBL-I	17.7 (5 <i>S</i> ,6 <i>R</i> )	1.9
	( <i>S</i> )-DNBL-C	9.1 (5 <i>S</i> ,6 <i>R</i> )	0.5
7-bromo-12-methyl-BA	( <i>R</i> )-DNBPG-I	20.9	0
<i>cis</i> -5,6-dihydrodiol ( <u>3</u> )	( <i>R</i> )-DNBPG-C	13.8 (5 <i>S</i> ,6 <i>R</i> )	1.0
(5e,6a)	( <i>S</i> )-DNBL-I	17.2 (5 <i>S</i> ,6 <i>R</i> )	2.1
	( <i>S</i> )-DNBL-C	10.6 (5 <i>S</i> ,6 <i>R</i> )	0.5

<sup>a</sup>The enantiomers were resolved with HPLC columns (4.6 mm i.d. x 25 cm; Regis Chemical Co., Morton Grove, IL) packed with an (*R*)-*N*-(3,5-dinitrobenzoyl)phenylglycine either ionically bonded ((*R*)-DNBPG-I) or covalently bonded ((*R*)-DNBPG-C) and an (*S*)-*N*-(3,5-dinitrobenzoyl)leucine either ionically bonded ((*S*)-DNBL-I) or covalently bonded ((*S*)-DNBL-C) to spherical particles of 5 micrometer diameter of  $\gamma$ -aminopropylsilanized silica.<sup>15,16</sup> HPLC was performed using a Waters Associates (Milford, MA) liquid chromatograph consisting of a Model 6000A solvent delivery system, a Model M45 solvent delivery system, a Model 660 solvent programmer, and a Model 440 absorbance (254 nm) detector. Samples were injected via a Valco model N60 loop injector (Valco, Houston, TX). Separation of enantiomeric dihydrodiols was achieved isocratically with a flow rate of 2 ml/min using premixed solvents of 10% (v/v) of ethanol/acetonitrile (2:1, v/v) in hexane at ambient temperature.

<sup>b</sup>Chiral stationary phases (CSP) are defined above.

<sup>c</sup>Retention time (R<sub>t</sub>) of the more strongly retained enantiomer. The absolute configurations of the more retained dihydrodiol enantiomers are indicated in parentheses.

<sup>d</sup>Resolution value (RV) =  $2(V_2 - V_1)/(W_2 + W_1)$ , where V is retention volume and W is peak width at base. The void time was 1.2 min.

<sup>e</sup> $\epsilon_{268} = 41800 \text{ cm}^{-1}\text{M}^{-1}$  (methanol);  $[\alpha]_D^{25} +97$  (c 0.54 mg/ml, methanol) for the 5*S*,6*R* enantiomer and -83 (c 0.62 mg/ml, methanol) for the 5*R*,6*S* enantiomer.

<sup>f</sup>Conformation of the hydroxyl group is indicated by a (quasiequatorial) and e (quasiaxial) in parenthesis.

<sup>g</sup>Resolution<sup>11</sup> and absolute configuration<sup>8</sup> of enantiomers were reported earlier and are included for comparison.

tion with *p*-*N,N*-dimethylaminobenzoyl chloride.<sup>2,8</sup> The CD spectrum of the dibenzoate (Fig. 1A) has a positive CD band with a maximum at 305 nm owing to the dipole-dipole interactions between the two benzoate groups. However, the expected exciton splitting with either a positive or a negative CD band at around 324 nm<sup>2,8</sup> was not observed. The lack of exciton chirality splitting is probably due to the dual conformations (quasiaxial and quasiequatorial) of both C<sub>5</sub>-O and C<sub>6</sub>-O bonds of **1**. When the conformations of C<sub>5</sub>-O and C<sub>6</sub>-O bonds of *cis*-dihydrodiols such as **2** are restricted in one of two possibilities, an exciton splitting was observed in the CD spectrum of its *bis-p*-*N,N*-dimethylaminobenzoate derivative.<sup>8</sup>

Since the absolute configuration of an enantiomeric **1** could not be determined by the exciton chirality CD method, a novel approach was taken to elucidate the absolute configuration of an enantiomeric *cis*-dihydrodiol of **1**. 7-Bromo-12-methyl-BA *cis*-5,6-dihydrodiol (**3**) was synthesized from 7-bromo-12-methyl-BA by reaction with OsO<sub>4</sub>.<sup>13</sup> Since **3** has a locked conformation (5-quasiequatorial-6-quasiaxial)<sup>7</sup>, the absolute configuration of an enantiomeric **3** can be determined by the exciton chirality CD method.<sup>2,8</sup> The bromo group of **3** can be removed by hydrogenolysis (tetrahydrofuran, H<sub>2</sub>/PtO<sub>2</sub>, 1 atm, 2 hrs).<sup>4-8</sup> Thus an enantiomeric **3** can be converted to an enantiomeric **1** with the absolute configuration unchanged. Hence the absolute configuration of an enantiomeric *cis*-dihydrodiol of **1** can be determined.




Figure 1. (A) CD spectra of an enantiomeric **1** (---,  $\epsilon_{\max}$  265 nm) more strongly retained by (*S*)-DNBL-I and its *bis-p*-*N,N*-dimethylaminobenzoate (—,  $\epsilon_{\max}$  310 nm). (B) CD spectra of an enantiomeric **3** (---,  $\epsilon_{\max}$  268 nm) less strongly retained by (*S*)-DNBL-I, its *bis-p*-*N,N*-dimethylaminobenzoate (—,  $\epsilon_{\max}$  313 nm), and its hydrogenolysis product (....,  $\epsilon_{\max}$  265 nm). Ar = *p*-*N,N*-dimethylaminobenzoyl. CD spectra were obtained using a JASCO model 500A spectropolarimeter equipped with a DP-500 data processor.

The enantiomeric **3** less strongly retained by (*S*)-DNBL-I was converted to a *bis-p-N,N*-dimethylaminobenzoate by reaction with *p-N,N*-dimethylaminobenzoyl chloride.<sup>2,8</sup> The dibenzoate was purified by reversed-phase HPLC.<sup>3,6,8</sup> The CD spectrum of the *bis-p-N,N*-dimethylaminobenzoate (Fig. 1B) showed a positive CD band with an ellipticity ( $\theta_{324}/A_{313}$ )<sup>8</sup> of +21.5 millidegrees due to the interacting transition moments of the benzoates. This positive CD chirality spectrum indicates that the enantiomeric **3** less strongly retained by (*S*)-DNBL-I has a *5R,6S* absolute stereochemistry.<sup>2</sup> This 7-bromo-12-methyl-BA (*5R,6S*)-dihydrodiol was converted to a 12-methyl-BA (*5R,6S*)-dihydrodiol by catalytic hydrogenolysis (57% yield).<sup>14</sup> Analysis of the hydrogenolysis product with an (*S*)-DNBL-I column indicated that racemization did not occur. The CD spectrum of the hydrogenolysis product (Fig. 1B) indicates that it is a mirror image to that of an enantiomeric **1** which is more strongly retained by (*S*)-DNBL-I column (Fig. 1A and Table 1). These procedures thus established that 12-methyl-BA (*5R,6S*)-dihydrodiol is more strongly retained by both ionically and covalently bonded (*R*)-DNBPG columns and is less strongly retained by both ionically and covalently bonded (*S*)-DNBL columns. This study also established the relationship between the absolute configurations and CD spectra of enantiomeric **1** and **3**.

**Acknowledgments:** This work was supported in part by Uniformed Services University of the Health Sciences Protocol No. R07502.

#### References and Notes:

1. P. P. Fu, F. E. Evans, D. W. Miller, M. W. Chou, and S. K. Yang, *J. Chem. Res. (S)* **1**, 158-159 (1983)
2. N. Harada and K. Nakanishi, *Acc. Chem. Res.* **5**, 257-263 (1972)
3. S. K. Yang and P. P. Fu, *Biochem. J.* **223**, 775-782 (1984)
4. P. P. Fu and S. K. Yang, *Biochem. Biophys. Res. Commun.* **109**, 927-934 (1982)
5. P. P. Fu and S. K. Yang, *Carcinogenesis* **4**, 979-984 (1983)
6. P.-L. Chiu, P. P. Fu, and S. K. Yang, *Biochem. Biophys. Res. Commun.* **106**, 1405-1411 (1982)
7. D. E. Zacharias, J. P. Glusker, R. G. Harvey, and P. P. Fu, *Cancer Res.*, **37**, 775-782 (1977)
8. S. K. Yang, M. Mushtaq, H. B. Weems, and P. P. Fu, *J. Liq. Chromatogr.*, in press
9. H. B. Weems and S. K. Yang, *Anal. Biochem.* **125**, 156-161 (1982)
10. S. K. Yang and X. C. Li, *J. Chromatogr.* **291**, 265-273 (1984)
11. S. K. Yang and H. B. Weems, *Anal. Chem.* **56**, 2658-2662 (1984)
12. S. K. Yang, H. B. Weems, M. Mushtaq, and P. P. Fu, *J. Chromatogr.* **316**, 569-584
13. R. G. Harvey, S. H. Goh, and C. Cortez, *J. Am. Chem. Soc.* **97**, 3468-3479 (1975)
14. 12-Methyl-BA *cis*-5,6-dihydrodiol (retention time 6.3 min) and 7-bromo-12-methyl-BA *cis*-5,6-dihydrodiol (retention time 8.7 min) were separated using a DuPont Zorbax ODS column (4.6 mm i.d. x 25 cm) eluted with methanol/water (3:1, v/v) at 1.5 ml/min.
15. W. H. Pirkle and J. M. Finn, *J. Org. Chem.* **46**, 2935-2938 (1981)
16. W. H. Pirkle; D. W. House, and J. M. Finn, *J. Chromatogr.* **192**, 143-158 (1980)

(Received in USA 4 November 1985)